scholarly journals Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

2010 ◽  
Vol 201 (3) ◽  
pp. 318-330 ◽  
Author(s):  
Signe Westring Worm ◽  
Caroline Sabin ◽  
Rainer Weber ◽  
Peter Reiss ◽  
Wafaa El‐Sadr ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Data Collection ◽  
Adverse Events ◽  
Hiv Infection ◽  
Antiretroviral Drugs ◽  
Drug Classes ◽  
Specific Individual ◽  
Hiv Drugs ◽  
Anti Hiv ◽  
Major Drug

scholarly journals Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study

HIV Medicine ◽  
2003 ◽  
Vol 4 (1) ◽  
pp. 1-10 ◽  
Author(s):  
M Law ◽  
N Friis-Moller ◽  
R Weber ◽  
P Reiss ◽  
R Thiebaut ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Data Collection ◽  
Adverse Events ◽  
Hiv Drugs ◽  
Anti Hiv

scholarly journals Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

2012 ◽  
Vol 15 (2) ◽  
Author(s):  
Kathy Petoumenos ◽  
Signe W Worm ◽  
Eric Fontas ◽  
Rainer Weber ◽  
Stephane De Wit ◽  
...  
Keyword(s):  
Data Collection ◽  
Adverse Events ◽  
Hiv Positive ◽  
Short Term ◽  
Hiv Drugs ◽  
Anti Hiv

scholarly journals Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

2019 ◽  
Vol 220 (10) ◽  
pp. 1629-1634 ◽  
Author(s):  
Lene Ryom ◽  
Jens Dilling Lundgren ◽  
Peter Reiss ◽  
Ole Kirk ◽  
Matthew Law ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Data Collection ◽  
Adverse Events ◽  
Confidence Interval ◽  
Protease Inhibitors ◽  
Incident Chronic Kidney Disease ◽  
Hiv Drugs ◽  
Anti Hiv

Abstract Background It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. Methods Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). Results The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5–10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2–1.6), but not exposure to DRV/r (1.0; .8–1.3), remained significantly associated with CKD. Conclusion While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.

scholarly journals Monitoring the safety of antiretroviral drugs in patients with HIV infection

2021 ◽  
Vol 13 (1) ◽  
pp. 115-123
Author(s):  
A. V. Matveev ◽  
A. E. Krasheninnikov ◽  
E. A. Egorova ◽  
E. I. Konyaeva
Keyword(s):  
Hiv Infection ◽  
Adverse Reactions ◽  
Antiretroviral Drugs ◽  
Electronic Database ◽  
Adherence To Treatment ◽  
Spontaneous Reports ◽  
Hiv Drugs ◽  
Anti Hiv

The antiretroviral therapy is a lifelong use of a combination of three or more antiretroviral drugs (ARVDs). One of the factors contributing to a significant decrease in patients’ adherence to treatment is the high toxicity of ARVs.The aim of the study is to study the safety of antiretroviral drugs retrospectively and based on spontaneous reports about adverse drug reactions (ADRs) inputted in the ARCADe database.Materials and method. The objects of our research were the 649 spontaneous messages about ARVDs recorded in the regional electronic database (register) of spontaneous messages for period 01 January 2009 — 31 December 2018.Results. Most often, ADR were registered with the use of combined ARVD and non-nucleoside reverse transcriptase inhibitors. Zidovudine and Efavirenz were the leaders in terms of the incidence of ARV ADR. Among the combined anti-HIV drugs, the most frequently ADR were associated with the use of a Lamivudine and Zidovudine combination.Conclusion. Long-term use of ARVs requires regular monitoring of adverse reactions, which will improve the quality of life of patients with HIV infection and significantly increase their compliance with antiretroviral pharmacotherapy.

Sign in / Sign up

Export Citation Format

Share Document